Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin plus pegylated liposomal doxorubicin in relapsed epithelial ovarian carcinoma
2011-000137-36Phase 2Active
- Sponsor
- Università Campus Bio-Medico di Roma
- Start
- Feb 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of trabectedin in epithelial ovarian cancer (EOC), sponsored by Università Campus Bio-Medico di Roma. Primary endpoint: Primary: toxicity and quality of life. Started Feb 2011; status: active.
02
Drugs
trabectedin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2011-000137-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000137-36.